Geron Corp Stock Price, News & Analysis

Geron Corporation (Nasdaq: GERN) has announced the launch of the IMpactMF Phase 3 clinical trial for imetelstat, a telomerase inhibitor targeting refractory myelofibrosis (MF). This trial aims to enroll approximately 320 patients and assess the drug's ability to extend overall survival and improve symptoms, following promising Phase 2 results. The primary endpoint will focus on overall survival, with secondary endpoints covering various clinical outcomes. The trial incorporates over 150 sites globally, though potential COVID-19-related delays are acknowledged.

Geron Corporation (Nasdaq: GERN) has achieved fifty percent enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). This milestone is crucial for advancing the trial, which aims to assess transfusion independence and disease-modifying effects of imetelstat. The trial is set to enroll approximately 170 patients, with top-line results expected in the second half of 2022, provided enrollment completes by mid-2021.

Imetelstat is the first telomerase inhibitor in development, offering a potential treatment alternative for MDS patients.

Geron Corporation (Nasdaq: GERN) announced multiple presentations at the 62nd ASH Annual Meeting, showcasing clinical data on imetelstat, their telomerase inhibitor. Key highlights include:

• 42% of patients in the IMerge Phase 2 trial achieved over 8-week red blood cell transfusion independence.
• Imetelstat showed potential disease-modifying activity in patients with relapsed/refractory myelofibrosis (MF), with significant reductions in mutation burden.
• Upcoming Phase 3 trials, IMerge and IMpactMF, aim to validate imetelstat’s efficacy in lower risk MDS and high-risk MF.

Geron Corporation (Nasdaq: GERN) announced presentations at the 62nd American Society of Hematology Annual Meeting, showcasing clinical data on imetelstat, its first-in-class telomerase inhibitor. Findings from the IMerge and IMbark Phase 2 trials evidence imetelstat’s disease-modifying activity and potential clinical benefits, particularly in lower risk myelodysplastic syndromes (MDS) and refractory myelofibrosis (MF). Key results include 42% of MDS patients achieving durable transfusion independence and significant improvements in overall survival among MF patients.

Geron Corporation (Nasdaq: GERN) announced the grant of a non-statutory stock option for 80,000 shares of its common stock to a newly-hired employee. This option was issued on November 18, 2020, at an exercise price of $1.90 per share, matching the closing price on the grant date. The option has a 10-year term and vests over four years, beginning with a 12.5% vesting after six months and the rest in monthly installments. This action complies with Nasdaq Listing Rule 5635(c)(4) and pertains to Geron's 2018 Inducement Award Plan.

Geron Corporation (Nasdaq: GERN) announced that its CEO, John A. Scarlett, will present a company overview at the Stifel Virtual Healthcare Conference on November 17, 2020, at 2:40 p.m. ET. A live audio webcast of the presentation will be accessible on Geron’s website, with an archived version available for 30 days post-event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor for hematologic myeloid malignancies. For more details, visit www.geron.com.

Geron Corporation (Nasdaq: GERN) reported a net loss of $19.7 million for Q3 2020, slightly higher than the $15.2 million lost in Q3 2019. Revenue for the third quarter was $108,000, compared to $131,000 for the same period last year. The company continues to advance its imetelstat program, despite COVID-19 related challenges that may delay trial enrollment. Geron has approximately $274 million in cash, expected to support operations until the end of 2022, and plans to begin two Phase 3 trials in early 2021.

Geron Corporation (Nasdaq: GERN) announced that ten abstracts related to imetelstat, its telomerase inhibitor, are accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting scheduled online from December 5-8, 2020. The abstracts highlight data from Phase 2 trials supporting ongoing Phase 3 studies in lower risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Notably, 42% of patients achieved red blood cell transfusion independence lasting over 20 months. The expected improvements in overall survival may mark significant advances in treating these conditions.

Geron Corporation (Nasdaq: GERN) will release its third quarter 2020 financial results on November 5, 2020, after market close. The results will be discussed in a conference call at 4:30 p.m. ET the same day. The press release will be available on the company’s website. A live webcast of the call will also be accessible, with archived options available for 30 days. Geron is focused on developing its telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies.